http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M#Head
http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M#assertion
http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M#provenance
http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M#pubinfo
http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M#assertion
http://purl.obolibrary.org/obo/DOID_9074
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_9074
http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB08879
http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M#association
http://www.w3.org/2000/01/rdf-schema#label
benlysta belimumab is indicated for the treatment of patients aged 5 years and older with active autoantibody positive systemic lupus erythematosus sle who are receiving standard therapy limitations of use the efficacy of benlysta has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus benlysta has not been studied in combination with other biologics or intravenous cyclophosphamide use of benlysta is not recommended in these situations benlysta is a b lymphocyte stimulator blys specific inhibitor indicated for the treatment of patients aged 5 years and older with active autoantibody positive systemic lupus erythematosus who are receiving standard therapy 1 limitations of use the efficacy of benlysta has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus benlysta has not been studied in combination with other biologics or intravenous cyclophosphamide use of benlysta is not recommended in these situations 1
http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB08879
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M#provenance
http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M#pubinfo
http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M#sig
http://purl.org/nanopub/x/hasSignature
RsG4q6KCP+7vJcZ+tdsV/cftvRGFAD5uwZ4IDUsLdCxrm7y0FwP2kII4umvQ5oWf6+kawHrIcWKviTre5y6EmU6eSV9Y79F1hEDdYJ59sw9eyXIV/qtm56FOV9H89p2ssGcIjgrG9h9lpempNEA2THPw8W6+/uAFFC4Tb2vvHgU=
http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M
http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M
http://purl.org/dc/terms/created
2021-07-03T14:55:22.169+02:00
http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs